Literature DB >> 32233587

The regulation of miR-139-5p on the biological characteristics of breast cancer cells by targeting COL11A1.

She Qun Gu1, Ji Hui Luo2, Wen Xiu Yao3.   

Abstract

Objective: This study aimed to explore the regulatory mechanism of miR-139-5p on the biological characteristics of breast cancer cells by targeting Collagen type XI alpha 1 chain (COL11A1). Method: GEO2R was used to identify the differentially expressed genes (DEGs) of breast cancer in GEO database. miRDB, miRanda and TargetScan databases were used to predict the miRNAs that regulate COL11A1. qRT-PCR was used to detect the expressions of COL11A1 and miR-139-5p in breast cancer cells, and western blot was used to detect the protein level of COL11A1. RNA binding protein immunoprecipitation assay was employed to test the targeted relationship between miR-139-5p and COL11A1, which was further verified by dual-luciferase reporter gene assay. CCK-8 assay was performed to detect the cell proliferation, and flow cytometry was carried out to examine the cell apoptosis. Moreover, western blot was used for the detection of caspase-3, Bax and Bcl-2 protein levels.
Results: A total of five DEGs were screened from the GEO database, of which COL11A1 was the only highly expressed in breast cancer. According to the database analysis, we predicted that miR-139-5p was much likely to target the expression of COL11A1. MiR-139-5p was poorly expressed in breast cancer cells and targeted inhibited COL11A1. Silencing COL11A1 or overexpressing miR-139-5p both could inhibit the proliferation and promote the apoptosis, while overexpressing the two factors simultaneously could reverse such effect.
Conclusion: Overexpression of miR-139-5p inhibits the proliferation and promotes the apoptosis of breast cancer cells by inhibiting the expression of COL11A1.

Entities:  

Keywords:  COL11A1 ; GEO2R ; apoptosis ; breast cancer ; miR-139-5p ; proliferation

Mesh:

Substances:

Year:  2019        PMID: 32233587     DOI: 10.3934/mbe.2020073

Source DB:  PubMed          Journal:  Math Biosci Eng        ISSN: 1547-1063            Impact factor:   2.080


  8 in total

1.  MiR-139-5p/ENAH Affects Progression of Hepatocellular Carcinoma Cells.

Authors:  Yueming Zhang; Meng Li; Yinghuan Qiu; Yuhua Wu; Shan Chen; Bin Ni; Ding Tang; Zhouzi Deng; Zhiqiang Hu
Journal:  Biochem Genet       Date:  2022-03-07       Impact factor: 1.890

2.  MicroRNA-139 Suppresses the Tumorigenicity of Triple Negative Breast Cancer Cells by Targeting SOX8.

Authors:  Liangliang Dong; Dongmei Zhou; Chunxia Xin; Bing Liu; Ping Sun
Journal:  Cancer Manag Res       Date:  2020-09-30       Impact factor: 3.989

3.  Identification of crucial noncoding RNAs and mRNAs in hypertrophic scars via RNA sequencing.

Authors:  Xiaodong Li; Zeliang He; Julei Zhang; Yan Han
Journal:  FEBS Open Bio       Date:  2021-05-12       Impact factor: 2.693

4.  miR-139-5p Was Identified as Biomarker of Different Molecular Subtypes of Breast Carcinoma.

Authors:  Haohang Sun; Ji Dai; Mengze Chen; Qi Chen; Qiong Xie; Weijun Zhang; Guoqing Li; Meidi Yan
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

Review 5.  Collagen XI Alpha 1 Chain, a Novel Therapeutic Target for Cancer Treatment.

Authors:  Yi-Hui Wu; Cheng-Yang Chou
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

6.  COL11A1 serves as a biomarker for poor prognosis and correlates with immune infiltration in breast cancer.

Authors:  Qi Luo; Jinsui Li; Xiaohan Su; Qiao Tan; Fangfang Zhou; Shaoli Xie
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

7.  MiR-139 Modulates Cancer Stem Cell Function of Human Breast Cancer through Targeting CXCR4.

Authors:  Chun-Wen Cheng; Wen-Ling Liao; Po-Ming Chen; Jyh-Cherng Yu; Hui-Ping Shiau; Yi-Hsien Hsieh; Huei-Jane Lee; Yu-Chun Cheng; Pei-Ei Wu; Chen-Yang Shen
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

8.  miR-335 Restrains the Aggressive Phenotypes of Ovarian Cancer Cells by Inhibiting COL11A1.

Authors:  Yi-Hui Wu; Yu-Fang Huang; Tzu-Hao Chang; Pei-Ying Wu; Tsung-Ying Hsieh; Sheng-Yen Hsiao; Soon-Cen Huang; Cheng-Yang Chou
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.